fda compounding semaglutide crackdown 2025 news Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots Compounded Ozempic Overdoses Likely Caused

Plans are more likely to cover a GLP-1 for an FDA-approved use such as type 2 diabetes, and many employer plans still exclude weight-loss coverage entirely

AMPK activation causes cells to utilize their stored fuel more efficiently, improving insulin sensitivity and glucose uptake into muscles

Retatrutide continues to be evaluated in additional Phase 3 studies across obesity and obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD)

It is currently under clinical investigation and has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)